Alere q A Molecular Platform for Global Health Diagnostics

Similar documents
WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere q HIV-1/2 Detect WHO reference number: PQDx

Alere Technologies GmbH

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Technical Bulletin No. 161

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

Xpert MTB/RIF Training. Indira Soundiram 2012

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

How best to structure a laboratory network with new technologies

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

TB Intensive San Antonio, Texas November 11 14, 2014

Diagnosis of drug resistant TB

Laboratory Diagnosis for MDR TB

Ken Jost, BA, has the following disclosures to make:

GeneXpert HIV-1 Quantitative assay Natasha Samsunder

Cepheid Update POC QA. Gwynn Stevens, PhD Director Virology Programme HBDC

TB 101 Disease, Clinical Assessment and Lab Testing

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

High-priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting

New Generation of Nucleic Acid Testing. Michele Owen, Ph.D Division of HIV/AIDS Prevention Centers for Disease Control & Prevention

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

Molecular assays in Tuberculosis. Jatin Yegurla Junior resident

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

Planning for the implementation of new diagnostic tests

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

WHO Prequalification of Diagnostics Programme PUBLIC REPORT

TB Laboratory for Nurses

Technical Bulletin No. 162

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Fully Integrated DNA Amplification Devices for Infectious Disease Diagnosis

Molecular Diagnostics

Detection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

Target product profiles for next generation TB diagnostics. Claudia Denkinger, MD PhD MSc Head of TB, FIND

HIV/AIDS DIAGNOSTICS TECHNOLOGY LANDSCAPE SEMI- ANNUAL UPDATE. January 2015

TPP for test that predicts progression to active TB

When good genes go bad

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

Treatment of Active Tuberculosis

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

In Vitro Diagnostic Platforms for the Developing World. David Kelso Oak Ridge April 20, 2012

CEPHIA Consortium for the Evaluation and Performance of HIV Incidence Assays STANDARD OPERATING PROCEDURE

Treating Patients, Not Disease: People-Centered Approach

A dynamic integrated drug, Mtb and host archetype for testing novel treatment interventions John I Fors

hiv/aids Diagnostics Technology Landscape october 2012

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose

AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS

WHO Prequalification of Diagnostics Programme PUBLIC REPORT Product: Pima CD4 Test Number: PQDx Abstract

LATITUDE Patient Management System

The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED

Update on CD4+ T-Cell Counting Technologies

The Molecular Epidemiology of Tuberculosis

Rapid and accurate detection of rifampin and isoniazid-resistant Mycobacterium tuberculosis using an oligonucleotide array

Heather Alexander, PhD

Received 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013

Polymer Technology Systems, Inc. CardioChek PA Comparison Study

Diagnosis and Management of Active Tuberculosis

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Carnitine / Acylcarnitines Dried Blood Spots LC-MS/MS Analysis Kit User Manual

TAP HERE TO SEE THE PRODUCT

Dr Francis Ogaro MTRH ELDORET

GLI model TB diagnostic algorithms

Multi-country surveillance project on fluoroquinolones and PZA resistance

American Association for Clinical Chemistry Emerging Clinical & Laboratory Diagnostics: The Portable Lab April 24-25, 2014

Rapid Diagnostics CHAI Experience. 6 th Moving Forward in Diagnostics Forum Les Pensieres November 7, 2012

CyBio Felix Your Automated Application Starts Here

Smart NDT Tools: A New Generation of NDT Devices

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

Laboratory s Role in the Battle Against Drug Resistant Tuberculosis

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

Diagnostics: Bench to Bedside Pathway

Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria

Step-by-Step Instructions For OraQuick HCV Rapid Antibody Test

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

Schedules of different training programs planned at NITRD under this WHO CC are given in the NITRD-WHOCC Training Schedules booklet.

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx

ncounter TM Analysis System

GeneXpert (Xpert MTB/RIF): what is the future?

Pyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India

Frances Jamieson, MD and Kevin May, BSc November 15 th,

LeadCare BLOOD LEAD ANALYZER. Quick Reference Guide

DETERMINE SPECIMEN REQUIREMENTS HIV-1/2 Ag/Ab Combo TESTING PROCEDURE

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: HIV 1/2 STAT-PAK Number: PQDx Abstract

Simple Solutions for Patient Monitoring. Maximum Flexibility 2 Configuration: 8 to 1000 viral load tests/day 2 Sample: Plasma/DBS

GLI model TB diagnostic algorithms

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Abbott RealTime HIV-1 (m2000sp) Number: PQDx

Transcription:

Alere q A Molecular Platform for Global Health Diagnostics Glenn Johns, Ph.D. Director, Global Health Diagnostics R&D 6 th Advanced Course on Diagnostics Annecy, France September 9, 2015

Alere q Complete Alere q External Battery Connectivity Module USB Printer Disposable Cartridge Compact and portable platform which delivers molecular results at the Point of Care 2

Alere q HIV-1/2 cartridge Sample Capillary Air channel Washing buffer Reagent chamber * Amplification and detection reagent includes specific primers and reporters Control window Lysis chamber * Capture reagent contains specific capture probe Reactor chamber * Probe array with specific probes & probes accommodating controls incl. IPC detection Waste Buffer Reservoir * modifications made to the current Alere q HIV-1/2 test for accommodating an Filovirus test on the Alere q cartridge

CMA: Array-Layout and Threshold Cycle Detection HIV-1_group O HIV-1_group M/N Index spots for alignment of an analysis grid Probes for HIV1 group M/N and group O and HIV2 Armored RNA internal process controls for HIV-1 and HIV-2 Positive/negative hybridization controls Change in signal Intensity indicates improper test run 4

Alere q HIV 1/2 Test Characteristics Intended Use Test Target Analyzer Instrument Sample Specimens Total steps required Diagnosis of HIV Infection (Detect) including Early Infant Diagnosis (EID) and monitoring of VL (VL WB, VL P) in HIV-positive patients Unspliced RNA of HIV-1 (M,N,O) and HIV-2 in whole blood or EDTA plasma Portable device <5kg weight; 20cmX20cmX29cm (W/H/L), no maintenance or calibration required Capillary whole blood, venous blood (EDTA) or EDTA plasma WB tests do not require any sample handling or pre-treatment by user Plasma test requires only plasma separation Alere q HIV 1/2 Detect Test Limit of Detection for 25µL sample 2491 cp/ml for HIV-1M [2046-3319 cp/ml] 943 cp/ml for HIV-1O [790-1262 cp/ml] 952 cp/ml for HIV-2 [794-1239 cp/ml] Diagnostic Specificity >99% HIV tests In the pipeline: Alere q HIV 1/2 WB VL Test Longitudinal studies to demonstrate clinical utility of fingerstick whole blood as sample Diagnostic Sensitivity >99,5% for HIV-1M ( 4000 cp/ml) 100% for HIV-2 ( 4000 cp/ml) Alere q HIV 1/2 Plasma VL Test 5

Alere q Pipeline: TB Detect and DST Profile 6

Microscopy Center Conditions 7

Conditions at Microscopy Centers Denkinger et al. Expert Rev. Mol. Diagn. 13(8), 763 767 (2013). Denkinger et al. Eur Respir J 2013; 42: 544 547 8

Alere q TB MDx Test Components Sputum Cup TB Detect Alere q Instrument Platform TB DST Profile 9

Workflow of the Alere q TB Detect test 10

Alere q TB DST Profile reflex test strategy 11

Alere q TB DST Profile reflex test strategy 12

Alere q DST Profile test design Multiplex assay for detection of SNP s associated with resistance to rifampin (rpob hot spot), isoniazid (katg) fluoroquinolones (gyra) and pyrazinamide (pnca) Probes representing wild type for all targets Probes representing corresponding mutations (RIF, INH, FQ) Additional probes for phylogenetic/silent SNP s within pnca Probe for control of MTB presence Probe for detection of fully integrated internal process control 13

signal signal Data processing for SNP resistance detection 1 Wild type 0,8 0,6 0,4 516wt_v03 516Val_v03 516Tyr_v03 0,2 0 81 77 73 69 65 61 57 53 49 45 41 37 33 temperature [ C] 1 0,8 0,6 0,4 Wild type 526wt_v03 526Asp_alt 526Tyr_alt 0,2 0 81 77 73 69 65 61 57 53 49 45 41 37 33 temperature [ C] 14

Alere Data Point Connectivity Analyzer USB Modems Alere SIMs Alere Data Point Portal Data Point Connectivity offering Data Point is the connectivity package that delivers analyser results to a central server enabling customers to access data remotely via the Data Point portal. Regardless of how many analyzers are in the field, the portal allows near real-time monitoring of data including usage patterns, device condition & stock management. The portal is also enabled with a flexible reporting & alerting system to alert program administrators to activity that is of interest to them on a near real-time or scheduled basis. 15 CONFIDENTIAL 15

Thank You! www.alerehiv.com glenn.johns@alere.com